Pharmaceutical company GSK has announced the appointment of Dr Harry C. Dietz to its board as an independent non-executive director and designated scientific and medical expert.
Dietz is a former president of the American Society of Human Genetics and is recognised as the world’s leading authority on a genetic disorder known as Marfan Syndrome. He also brings experience in development of novel therapies through his role as founder of biopharmaceutical company Blade Therapeutics.
Dietz will join the GSK board on 1 January 2022.